Status:
UNKNOWN
Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox
Lead Sponsor:
Assiut University
Conditions:
β-thalassemia
Eligibility:
All Genders
16-65 years
Brief Summary
Regular blood transfusions are essential for the management of haematological conditions such as β-thalassemia major. As a result, however, patients with these conditions are susceptible to the develo...
Detailed Description
In the absence of a naturally occurring physiological mechanism for the removal of excess iron in the body, life-long treatment and adherence to iron chelation therapy (ICT) are necessary to prevent t...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- 1 - Age more than 16 years 2-transfusion related iron over load (serum ferritin more than 1000 ng/ml) 3-patients on oral iron chelation (deferasirox ) for one year or more
- Exclusion
- primary haemochromatosis
- thalassemia minor patients
- preseance of systemic disease that prevent patient from treatment ,
Exclusion
Key Trial Info
Start Date :
December 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2020
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT03358498
Start Date
December 1 2017
End Date
March 1 2020
Last Update
November 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University Hospital
Asyut, Egypt, Assiut University71515